A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effect of hepatic impairment on the pharmacokinetics,
pharmacodynamics, safety and tolerability of GK Activator (2) in type 2 diabetes patients
with mild and moderate hepatic impairment. Patients with type 2 diabetes, and with normal
hepatic function, or mild or moderate hepatic impairment, will receive a single dose of GK
Activator (2) 100mg po before breakfast, for assessment of pharmacokinetic, pharmacodynamic
and safety parameters. The anticipated time on study treatment is <3 months, and the target
sample size is <100 individuals.